|Bid||0.00 x 1800|
|Ask||0.00 x 36100|
|Day's Range||25.40 - 25.44|
|52 Week Range||9.59 - 29.55|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 13, 2018 - Nov 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.06|
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the first quarter, which unveil their equity positions as of March 31. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
Nasdaq: NITE), a clinical-stage gene therapy company, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of the acquisition, Biogen now has added two mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology.
Nightstar Therapeutics plc (“Nightstar”) is pleased to announce that the High Court of Justice of England and Wales today sanctioned the scheme of arrangement under Part 26 of the Companies Act pursuant to which Tungsten Bidco Limited, a newly-incorporated company and wholly-owned indirect subsidiary of Biogen Inc., will acquire the entire issued and to be issued share capital of Nightstar (the “Acquisition”). All Conditions to the Acquisition have now been satisfied or waived other than delivery to the Registrar of Companies of England and Wales of a copy of the Court Order, which is expected to take place on 7 June 2019, at which point the Scheme will become Effective. Full details of the Acquisition are set out in the combined circular and proxy statement dated 9 April 2019 (the “Scheme Document”).
Nightstar Therapeutics plc (“Nightstar”) is pleased to announce an update to the expected timetable of events relating to the scheme of arrangement (the “Scheme”) pursuant to which Tungsten Bidco Limited, a newly-incorporated company and wholly-owned indirect subsidiary of Biogen Inc., will acquire the entire issued and to be issued share capital of Nightstar. The Scheme remains subject to certain conditions including sanction by the Court at the Court Hearing, which will now take place on 5 June 2019 (as opposed to 6 June 2019 as previously announced), and the delivery of a copy of the Court Order to the Registrar of Companies. Subject to the Scheme receiving the sanction of the Court and the delivery of a copy of the Court Order to the Registrar of Companies, the Scheme is still expected to become effective on 7 June 2019.
It's not a secret that every investor will make bad investments, from time to time. But serious investors should think...
Nightstar Therapeutics plc ("Nightstar") is pleased to announce that, at the General Meeting and the Court Meeting held earlier today in connection with the recommended acquisition of the entire issued and to be issued share capital of Nightstar by Tungsten Bidco Limited, a newly-incorporated company and wholly-owned indirect subsidiary of Biogen Inc., all resolutions proposed were passed by the requisite majorities and accordingly the Scheme was approved. Details of the resolutions passed are set out in the notices of General Meeting and Court Meeting at pages ix to xiii and vi to viii respectively of the combined circular and proxy statement dated 9 April 2019 (the "Scheme Document"). The detailed voting results in relation to the General Meeting and Court Meeting are set out below.
Nightstar Therapeutics plc ("Nightstar") (NITE) today announced that both leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”), have recommended that Nightstar shareholders vote "FOR" the proposals relating to the proposed acquisition of Nightstar by an affiliate of Biogen Inc. (“Biogen”). To become effective, the transaction must be approved by Nightstar shareholders at a special General Meeting and at a Court Meeting convened by the High Court of Justice in England and Wales. Both the General Meeting and the Court Meeting will be held at the offices of Nightstar’s solicitor, Skadden, Arps, Slate, Meagher & Flom LLP at 40 Bank Street, London, United Kingdom E14 5DS.
NEW YORK , April 23, 2019 /PRNewswire/ -- Advanced Disposal Services, Inc. (ADSW) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the proposed sale ...
Nightstar Therapeutics plc ("Nightstar") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to the recommended acquisition of the entire issued and to be issued share capital of Nightstar by Tungsten Bidco Limited ("Bidco"), a newly-incorporated company and wholly-owned subsidiary of Biogen Switzerland Holdings GmbH (the "Acquisition"). Nightstar has also received notice from Bidco’s representatives that the German Federal Cartel Office will not assert jurisdiction to review the Acquisition.
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating whether the sale of Nightstar Therapeutics plc (“Nightstar” or the “Company”) (NITE) to Biogen Inc. (“Biogen”) is fair to Nightstar shareholders. If you are a Nightstar shareholder and would like to discuss your legal rights and options, please visit Nightstar (NITE) Merger Investigation or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or email@example.com or firstname.lastname@example.org.
On 4 March 2019, the board of Nightstar Therapeutics plc ("Nightstar") and Biogen Switzerland Holdings GmbH ("Bidder"), a subsidiary of Biogen, Inc., announced that they had reached agreement on the terms of a recommended acquisition whereby the entire issued and to be issued share capital of Nightstar will be acquired by Tungsten Bidco Limited ("Bidco", a newly-incorporated company and wholly-owned subsidiary of Bidder) (the "Acquisition"). The Acquisition is to be effected by means of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme") and is subject to the terms and conditions set out in the scheme document relating to the Acquisition (the "Scheme Document").
Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.
NEW YORK , April 1, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
Investing in biotech stocks has its up days and its down days. For investors in Biogen (NASDAQ:BIIB) -- and more importantly millions of Alzheimer's patients around the world -- yesterday was a down day. On Thursday, Biogen stock plunged more than 30% on the cancelation of stage 3 clinical trials for a blockbuster Alzheimer's medication.Source: Shutterstock The massive drop was truly an unsettling surprise for BIIB shareholders as the drug was seen as a multi-billion blockbuster and game-changing medication for treating the disease. It really did come out of nowhere. The question now is whether to cut bait or fish. Was the drop enough to get investors excited about Biogen stock again?Given its huge revenue drivers, now cheaper price and still large pipeline, the answer is a resounding yes.InvestorPlace - Stock Market News, Stock Advice & Trading Tips What Happened at Biogen?Biotech stocks trade based on expectations. Something positive happens and then investors send the stock skyward and wait for the next big event to occur. It's all about what's coming down the runway. Expectations build upon that. This is true for large biotech stocks as well.For Biogen, the expectation build-up had to do with its Alzheimer's drug candidate aducanumab. The drug was in the class of monoclonal antibody medications. Basically, aducanumab was designed to break down the beta-amyloid plaques that can build up in the brain. These amyloids interfere with communication between brain cells and cause Alzheimer's and mild dementia. Back in 2014, BIIB saw some serious success with aducanumab during an early-stage study. It actually seemed to reduce the build-ups. * 7 Retail Stocks That Will Continue to Rebound in 2019 Thanks to this very positive early trial, Biogen decided to skip over smaller phase 2 studies and move the medication into larger and more advanced stage 3 testing. The idea was that Biogen could skip through the process and land a Food and Drug Administration (FDA) approval much faster. And there was a good chance for that considering how well it did early on.For Biogen stock, this would have been a major win on several fronts.For starters, there have not been any new Alzheimer's therapies approved in more than 15 years. meanwhile, the Alzheimer's Association pegs more than 5.8 million Americans currently living with the disease. Biogen was looking at a potential blockbuster with huge revenue implications. And it potentially needs that revenue to fill the coming declines in its multiple sclerosis portfolio.Unfortunately for BIIB and Alzheimer's patients, they'll have to wait a bit longer.Biogen and its partner Eisai reported that they would discontinue two late-stage trials for the drug after doing a futility analysis. An independent data-monitoring committee came to the conclusion that aducanumab was "unlikely to meet the primary endpoints" in either study.With expectations for the company to score a major blockbuster, investors abandoned Biogen stock. BIIB fell 30% -- or $90 per share -- and had its worst day of trading in nearly 2 decades. Biogen Stock May Be Worth SnaggingBiogen stock's loss was tremendous and goes to show just how much investors were valuing the drug as part of BIIB's future prospects. But perhaps, investors have taken Biogen down too much on the news.For starters, Biogen isn't a fly by night clinical-stage biotech stock. It's just the opposite. The firm has a portfolio of some pretty big blockbusters already. Thanks to winners like Spinraza and Tysabri, BIIB's portfolio managed to see a 10% jump in sales last year to more than $13.45 billion. Moreover, that portfolio managed to generate more than $5.3 billion in free cash flows and impressive earnings.And it's using those profits in a smart way. The key is that Biogen has been building a full pipeline to create a multi-franchise neurology portfolio. This includes its recent buyout of retinal degeneration specialist Nightstar Therapeutics (NASDAQ:NITE). So yes, losing Alzheimer's does stink, but the biotech's rich pipeline and cash flows give it plenty of wiggle room to buy or develop a pipeline. According to CFO Jeff Capello, adding up cash flows, cash on hand and its ability to leverage up and "you get a $37 billion number, which gives us a lot of capacity to add to the business."It's a song and dance we've heard plenty of times before. But Biogen has the firepower to make it work. It can buy a pipeline successfully.For that pipeline potential and drugs already producing revenues, Biogen stock is going for dirt cheap. After yesterday's 30% haircut, you can now snag the biotech firm at just 8.7x free cash flows and a trailing P/E of just 10.50. That's bargain-basement pricing for a biotech leader. For example, Amgen (NASDAQ:AMGN) can be had for a P/E of 14, while Gilead Sciences (NASDAQ:GILD) is closer to 16. Nibbling at Biogen StockGiven the steep drop and perhaps overreaction that sent Biogen stock into extreme value territory, investors with a longer-term timeline may want to consider snagging some of the firm's shares. * 7 Beaten-Up Stocks to Buy as They Reverse Course The lost of the Alzheimer's drug does hurt, but BIIB still has plenty in the tank to get it through. And with today's valuations, there's a decent margin of safety associated with shares. The time to start buying could be now.Disclosure: At the time of writing, Aaron Levitt held a long position in the iShares NASDAQ Biotechnology Index (IBB) -which holds GILD, BIIB and AMGN. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks That Will Continue to Rebound in 2019 * 5 Stocks To Buy for the Happiest Employees * 7 ETFs for a Millennial Portfolio Compare Brokers The post Biogen Stock Fell Too Far on Unfortunate News appeared first on InvestorPlace.
HENDERSON, NV / ACCESSWIRE / March 8, 2019 / The past few weeks have been busy with big bio taking over smaller biotechs developing novel therapies. Roche (RHHBY) said it would spend $4.8 billion in a ...
Biogen's pending acquisition of gene therapy player Nightstar Therapeutics only offers a "modest pipeline boost," an analyst said Tuesday. Nightstar is working on therapies for eye diseases.
Biogen Inc (NASDAQ: BIIB ) announced Monday a deal to buy gene therapy biotech Nightstar Therapeutics PLC (NASDAQ: NITE ) for $800 million. The Analysts Baird analyst Brian Skorney maintained a Neutral ...